ACET Share Price Performance
US$6.47
-5.61 (-46.44%)
Price US$6.47
Share Pricen/a
Adicet Bio, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
ACET Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Adicet Bio, Inc. Key Details
About ACET
- Founded
- 2014
- Employees
- 102
- CEO
- WebsiteView website
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
